SCHEMBL3238459

SCHEMBL3238459

Nc1nc(O)c2c(n1)CC(c1ccccc1)CC2

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.48
LMNA P02545 1/20 0.48
POLB P06746 1/20 0.48
GAA P10253 1/20 0.48
TSHR P16473 1/20 0.48
MAPK1 P28482 1/20 0.48
HTT P42858 1/20 0.48
HSD17B10 Q99714 1/20 0.48
HRH4 Q9H3N8 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47
HSP90AA1 P07900 1/20 0.45
HSP90AB1 P08238 1/20 0.45
ACHE P22303 2/20 0.41
ADRA1A P35348 1/20 0.40
HCAR2 Q8TDS4 1/20 0.40
ALDH1A1 P00352 1/20 0.38
DAPK3 O43293 1/20 0.38
JAK2 O60674 1/20 0.38
CSF1R P07333 1/20 0.38
RET P07949 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3339642 0.92 HRH3 (0.55) MAPTLMNAPOLBGAATSHR
SCHEMBL3242652 0.87 HRH3 (0.36) MAPTLMNAPOLBGAATSHR
SCHEMBL3236494 0.84 ADRA1A (0.47) MAPTLMNAPOLBGAATSHR
SCHEMBL3241055 0.83 HSP90AA1 (0.48) MAPTLMNAPOLBGAATSHR
SCHEMBL3233963 0.81 ACHE (0.35) MAPTLMNAPOLBGAATSHR
SCHEMBL3230195 0.81 ADRA1A (0.45) LMNAMAPK1HTTACHEADRA1A
Bicarbonate SCHEMBL3236891 0.80 HCAR2 (0.47) LMNAMAPK1HTTHSP90AA1HSP90AB1
SCHEMBL3236472 0.78 LMNA (0.33) MAPTLMNAPOLBGAATSHR
SCHEMBL603923 0.77 HRH4 (0.60) MAPTLMNAPOLBGAATSHR
SCHEMBL8634448 0.77 LMNA (0.54) MAPTLMNAPOLBGAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298289-A1 HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS UCB PHARMA, S.A. (BE) 2010-11-25 US claimed
EP-2209775-A1 HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS UCB Pharma, S.A. (BE) 2010-07-28 EP claimed
WO-2009047255-A1 HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS UCB PHARMA, S.A. (BE) 2009-04-16 WO claimed
US-20100298289-A1 HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS UCB PHARMA, S.A. (BE) 2010-11-25 US disclosed
EP-2209775-A1 HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS UCB Pharma, S.A. (BE) 2010-07-28 EP disclosed
WO-2009047255-A1 HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS UCB PHARMA, S.A. (BE) 2009-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298289-A1 HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS HRH4, HRH2, HRH3 MAPT 2784/4885LMNA 4485/4885POLB 4039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.